Bajaj HealthCare Limited

BAJAJHCARE

INE411U01027

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:53 28/06/2024 pm IST			5-day change	1st Jan Change
336 ^INR	+0.83%		+3.67%	-10.58%

24/05	Bajaj HealthCare Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
24/05	Bajaj HealthCare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

US Food and drug administration Conducts its Pre Approval inspection at Bajaj HealthCare Limited's API Facility

November 18, 2022 at 10:48 am IST

Bajaj HealthCare Limited announced that, US Food and drug administration (USFDA) has conducted it's pre approval inspection of its API facility located at Vadodara, Gujarat from November 14, 2022 to November 17,2022. The pre-approval inspection of United State Food and Drug Administration (USFDA) has completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited.

Latest news about Bajaj HealthCare Limited

Bajaj HealthCare Limited Reports Earnings Results for the Full Year Ended March 31, 2024	24/05	CI
Bajaj HealthCare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	24/05	CI
Bajaj Healthcare Limited Recommends Final Dividend for the Financial Year Ended 31St March, 2024	24/05	CI
Bajaj Healthcare Appoints CFO	07/05	MT
Bajaj Healthcare Limited Appoints Dayashankar Patel as the Chief Financial Officer	06/05	CI
Bajaj Healthcare Bags Contract Manufacturing for APIs from UK, EU Customers; Shares Jump 14%	28/02	MT
Bajaj Healthcare Limited Enters Definitive CDMO Agreement for 15 APIs with UK/EU Customers	28/02	CI
Indian Equities Rebound, Helped by Gains in IT, Auto and Metal Stocks	22/02	MT
Bajaj Healthcare CFO Steps Down	12/02	MT
Bajaj Healthcare Limited Announces Executive Changes	09/02	CI
Bajaj Healthcare Limited Announces Resignation of Rupesh Nikam as Chief Financial Officer	09/02	CI
Bajaj HealthCare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Bajaj Healthcare Limited Announces Resignation of Aakashkumar Keshari from the Post of Company Secretary & Compliance Officer Effective	03/02	CI
Bajaj Healthcare Limited Announces Resignation of Avinash K. Dalal as Non-Executive Independent Director	26/12	CI
Bajaj Healthcare Appoints Chief Technical Officer	10/11	MT
Bajaj Healthcare Limited Approves Appointment of Amit Rajan as Chief Technical Officer	09/11	CI
Bajaj HealthCare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Bajaj Healthcare Commissions Alkaloid Extraction Plant	19/23/19	MT
Bajaj Healthcare Completes Constrution of Alkaloid Extraction Plant in Gujarat, India	16/23/16	MT
Bajaj Healthcare Limited Announces Successfully Completion of Construction of Alkaloid Extraction Plant at Vadodara, Gujarat Unit	13/23/13	CI
Bajaj Healthcare Gets Vadodara, India Unit Inspection Report from US FDA	14/23/14	MT
Bajaj Healthcare Swings to Loss in Fiscal Q1	16/23/16	MT
Bajaj HealthCare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Bajaj HealthCare Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Bajaj HealthCare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI

Chart Bajaj HealthCare Limited

Duration

Period

More charts

Company Profile

Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. It also offers Inositol Nicotinate and Magnesium L-Threonate.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAJAJ HEALTHCARE LIMITED	-10.58%	111M
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B